DENOVX, LLC — Department of Health and Human Services SBIR Phase I: 100

Description

DESCRIPTION provided by applicant Drug shortages negatively affect Public Health by causing treatment delays medication errors and by increasing healthcare costs from the need for ad hoc patient management strategies to cope with the shortage Continuous flow crystallization a process in which crystalline material is generated under dynamic flow conditions requires very high concentrations supersaturation of the Active Pharmaceutical Ingredient API which can degrade the quality of the product and manufacturing process These issues can be resolved by inducing crystallization at lower supersaturations using surface chemistry modifications The product of this SBIR will be continuous flow crystallization modules that contain nucleation surfaces allowing for rapid scale up manufacturing of a broad spectrum of APIs in response to therapeutic drug shortages Public Health benefits accrue from the expanded use of continuous flow crystallization and the QC efficiencies and economic savings that can offset shortages attributable to quality issues and business discontinuation shortages The overarching innovation of combining cost effective tunable enhanced nucleation surfaces with continuous flow crystallization represents a disruptive scalable platform of broad relevance in responding to API and drug shortages The long term objective is to develop nucleation enhanced continuous flow crystallization modules that are effective in managing drug shortages and in the manufacture of orphan specialty e g pediatric geriatric and commercially relevant APIs The Phase I hypothesis is that enhanced nucleation surfaces can be incorporated into continuous flow crystallization to improve crystallization rates without adversely affecting the API crystal size and size distribution The Specific Aims are For a given set of conditions demonstrate a improvement in average crystal size size distribution or throughput for nucleation enhanced vs conventional flow crystallization and Develop and demonstrate a nucleation enhanced continuous flow crystallization module capable of manufacturing kilogram quantities of crystalline EGCg to overcome a current shortage of this API Ketoconazole will also be studied if the budget and timing allow Plans for Phase II emphasize an expansion of API targets For example ketoconazole Two drugs with current shortages dexamethasone and sufentanil citrate And others defined in consult with NIH DeNovX operates with a high value products and services model in a $ M M addressable market and the Go to Market strategy will leverage appropriate strategic partnerships with CROs CMOs and API equipment manufacturers PUBLIC HEALTH RELEVANCE Drug shortages negatively affect Public Health by causing treatment delays medication errors and by increasing healthcare costs from the need for ad hoc patient management strategies to cope with the shortage A positive impact to Public Health will derive from the proposed application of continuous manufacturing technologies which can accelerate response times when drug shortages do occur and can offer a technology solution that reduces shortages attributable to quality issues and business discontinuation shortages that result from high manufacturing costs